ClinicalTrials.gg

Short Bowel Syndrome clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 159 studies for Short Bowel Syndrome across more than 10 countries. 24 are recruiting or about to start. 127 of them are mainly about Short Bowel Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-28.

Status

Completed
90
Recruiting
18
Terminated
14
Withdrawn
11
Status unknown
10
Active, not recruiting
6

Phase

Phase 3
35
Phase 2
26
Phase 4
13
Phase 1
11
Early Phase 1
2

Where

United States
80
France
26
Denmark
22
United Kingdom
20
Germany
17
Belgium
16

Who develops what

Add Short Bowel Syndrome to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 7 programs from 7 companies, 6 with this as their studies’ main aim; 3 with a live phase 3 study; 5 primary completions in the next 12 months. Compare Changchun GeneScience Pharmaceutical, Chongqing Peg-Bio Biopharm and Ironwood Pharmaceuticals here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
teduglutideApproved: US 2012 · EU☆ Track1 live phase-3 study: NCT06973304Takeda
apraglutide☆ Track2 live phase-3 studies: NCT07742735, NCT05018286Ironwood Pharmaceuticals, Inc.
glepaglutide☆ Track2 live phase-3 studies: NCT07197944, NCT07228403Zealand Pharma

The 3 in phase 3 with the nearest primary completion, of 7 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (5)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 10 Feb 2027 est.teduglutide · Takeda · Phase 3 main aimNCT06973304 A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome — primary endpoint: Percentage of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Week 20 and Maintained Through Week 24 · 13 enrolled
  • Mar 2027 est.Crofelemer Powder for Oral Solution · Napo Therapeutics, S.p.A. · Phase 2 main aimNCT06904872 Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC) — primary endpoint: Safety and Tolerability · 18 enrolled
  • 15 Apr 2027 est.FT1 · Chongqing Peg-Bio Biopharm Co., Ltd. · Phase 2 main aimNCT07704047 A Clinical Study of FT1 in Patients With Short Bowel Syndrome — primary endpoint: Treatment-related Adverse Events · 8 enrolled

2 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Short Bowel Syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here GLP-1 receptor agonists 3

Coming up

11studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger. 9 (50%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (11%) take healthy volunteers.

Recruiting studies that take each age, of 18
AgeWomenMen
108 (44%)8 (44%)
1815 (83%)15 (83%)
3012 (67%)12 (67%)
4012 (67%)12 (67%)
5012 (67%)12 (67%)
6512 (67%)12 (67%)
7510 (56%)10 (56%)
8510 (56%)10 (56%)

Across all 159 studies, recruiting or not: 42% stop at 75 or younger and 36% at 65; 48% take children; 0% are for women only and 1% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Short Bowel Syndrome studies take

Of 27 phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 37 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 337 mo24–46 · 27 studies36 mo20–45 · 26 studies—
Interventional, no phase22 mo19–59 · 24 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 159. Browse all 159 → or search them.